Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Current Liabilities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Total Current Liabilities for 4 consecutive years, with $20.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 84.42% to $20.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.2 million through Dec 2025, down 84.42% year-over-year, with the annual reading at $20.2 million for FY2025, 84.42% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $20.2 million at Century Therapeutics, down from $22.0 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $129.8 million in Q4 2024, with the low at $14.5 million in Q1 2025.
  • Average Total Current Liabilities over 4 years is $27.6 million, with a median of $20.3 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 627.23% in 2024, then crashed 84.42% in 2025.
  • Over 4 years, Total Current Liabilities stood at $29.8 million in 2022, then crashed by 40.15% to $17.8 million in 2023, then surged by 627.23% to $129.8 million in 2024, then plummeted by 84.42% to $20.2 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $20.2 million, $22.0 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.